Karius sees a world where infectious disease is no longer a major threat to human health.
With the Karius Test™, we deliver unprecedented diagnostic insight to enable physicians to make rapid treatment decisions.
We are a team of clinicians, molecular biologists, data scientists, software engineers, and commercial experts drawn together by a shared commitment to improve patient health.
By using genomics and AI to map a patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
The Karius Test has been adopted by leading hospitals and transplant centers throughout the US
Infectious diseases are a leading cause of global mortality and an enormous area of unmet need. The Karius Test allows clinicians to diagnose infections more rapidly and accurately, helping them to devise precise and effective treatment plans for patients with the objective of speeding their recovery times.
I’m excited for future applications of our technology to combat infectious diseases worldwide.
Join us at our next event
In the news: See what people are saying about Karius
Chief Executive Officer
Alec has over 30 years of experience in the genomics, pharmaceutical, and biotechnology industries, and has a proven track record driving commercial growth and performance for businesses in highly competitive and regulated biomedical markets. He was previously the Chief Operating Officer for Myriad Genetics, a molecular diagnostic company. During his time at Myriad, he launched new products and scaled new business units in Women’s Health, Oncology, Urology, and Prenatal screening. Previously, Alec has held leadership positions at Novartis, Sanofi-Aventis, Nektar Therapeutics, and Pfizer. Alec is a founding board member of BioUtah, Utah’s life sciences trade association.
Mickey Kertesz, PhD
President and Chief Product Officer
Mickey co-founded Karius in 2014 to bring the pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Prior to that, he was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Mickey earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to complete his postdoctoral work in bioengineering at Stanford University, where he developed novel methods for investigating the genetic diversity of human viruses.
Tim Blauwkamp, PhD
Chief Scientific Officer
Tim, co-founder of Karius, is a biomedical scientist with 15 years’ experience managing and conducting research in molecular biology, regenerative medicine, and next-generation sequencing. He was previously Head of Molecular Biology at Moleculo, where he ran scientific research and lab operations until the company’s acquisition by Illumina. He continued to lead a technology development group within Illumina, creating new genomics tools and authoring several patent applications. He obtained a PhD in biological chemistry from the University of Michigan. His postdoctoral work at Stanford University and the University of Michigan led to several novel tools and insights into the molecular mechanisms governing human development.
Sivan Bercovici, PhD
Chief Technology Officer
Sivan is an innovator in artificial intelligence, pioneering the development of complex computational and data platforms, as well as novel machine-learning models designed to address critical challenges in human disease. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode, where he led the development of the analytical platform and validation of several clinical assays across oncology and rare hereditary diseases. He holds a Ph.D. in Computer Science from the Technion – Israel Institute of Technology, and continued to Stanford’s Artificial Intelligence Lab to pursue his post-doctoral research.
Chief Commercial Officer
Rachel is a proven commercial executive with expertise in building highly effective sales and marketing programs resulting in market leadership. Known for her ability to establish, scale and direct high performing and cohesive teams, Rachel is an influential leader who quickly builds trust and rapport. Prior to joining Karius, Rachel was CCO at BioFire Diagnostics where she built and led the commercial team responsible for the launch of syndromic infectious disease diagnostics to annual global sales greater than $1B.
Bradley Perkins, MD
Chief Medical Officer
Brad is a physician, scientist, and entrepreneur with extensive experience in microbial and human genomics research, application, and commercialization. At the Centers for Disease Control and Prevention (CDC), he led the anthrax bioterrorism investigations following 9/11, and later served as CDC’s Chief Strategy and Innovation Officer. More recently, he was EVP for Strategy and Innovation at Vanguard Health Systems, and he was the founding Chief Medical Officer for Human Longevity Inc., working with genomics pioneer JC Venter. Brad is board-certified in Internal Medicine.
VP, Head of Human Resources
Stacy is a strategic, versatile, and business-focused Human Resources leader leveraging a wealth of experience developing and delivering on HR strategies for organizations undergoing rapid growth and change. She has a passion for building HR infrastructure from the ground up while partnering with leaders to meet their business objectives through people strategies. She is an influencer, thought leader, and change agent who applies expertise to complex business issues to develop innovative solutions. Stacy is committed to creating a dynamic and diverse work environment that fosters a culture of inclusion, innovation, collaboration and creativity where employees are enabled to achieve their greatest potential.
Asim A. Ahmed, MD
Senior Medical Director, Medical Affairs
Asim is a physician-scientist trained in pediatric infectious diseases. He obtained his M.D. from Baylor College of Medicine and performed an HHMI medical student fellowship at UCSF. He completed his residency at The Children’s Hospital of Philadelphia and fellowship in infectious diseases at Boston Children’s Hospital where he developed systems to study the entry mechanisms of flaviviruses, alphaviruses and henipaviruses. In addition to his work on metagenomic next-generation sequencing for infectious diseases he has an extensive clinical expertise in encephalitis, emerging viruses and vector-borne diseases.
Meredith Reichert, PhD
VP Corporate Strategy and Development
Meredith is a proven business strategist that brings a uniquely scientific background to the role of corporate development. Meredith integrates scientific, technical, clinical and commercial insights to drive corporate strategy, business development, and investor relations for Karius. Prior to joining Karius she was an Associate Partner at McKinsey and Company in the healthcare practice, where she specialized in developing growth strategies for precision medicine companies, led clinical and partnership strategies with national healthcare providers, and developed successful market entry approaches for both diagnostic and therapeutic products. She holds both a Ph.D. in Neurobiology and Behavior and a BS in Biochemistry and Molecular Biology.
Senior Director, Finance & Controller
Karen brings over 15 years of corporate accounting and finance operations experience from start-ups to Fortune 500 organizations in health technology, and life sciences. Her experience ranges from M&A integration, systems implementation to facilitate budgets and forecasting for U.S. operations. Previously she served various managerial positions at Stentor, Philips, and Fluidigm. She received her Bachelor of Science degree in Accounting from San Diego State University and is a Certified Public Accountant.
Judith Wilber, PhD
Judy has broad experience in technology development and clinical utilization of new biomarkers and technologies, having held positions as Vice President of Technical Operations and Clinical Laboratory Director at CareDx (formerly XDx); Vice President of Research in Nucleic Acid Diagnostics at Bayer Healthcare (formerly Chiron Diagnostics), where she established in-house clinical reference laboratories in the US and Europe and led studies to prove the clinical value of viral load measurement.